cannabis

WASHINGTON - In a significant shift in federal drug policy, the Department of Health and Human Services (HHS) has recommended reclassifying cannabis from a Schedule I to a Schedule II substance, acknowledging the plant's medical…

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.Once a quintessential US swing state that could decide general elections, Ohio has drifted to the right. It voted…

Investing in cannabis stocks isn't for everyone, but with the green-leafed drug now fully legalized in 23 states and Washington, D.C., the sector may be ripe for growth opportunities. Despite the industry's facing ongoing legality,…

Specifically, the federal Health and Human Services Department has recommended taking marijuana out of a category of drugs deemed to have “no currently accepted medical use and a high potential for abuse.” The agency advised moving pot…

© Reuters. A woman holds marijuana for sale at the MedMen store in West Hollywood, California U.S. January 2, 2018. REUTERS/Lucy Nicholson By Niket Nishant and Tanay Dhumal (Reuters) -Mastercard has told financial institutions to…

Last week, Tikun Olam-Cannbit Pharmaceuticals (TASE: TKUN) made an announcement heralding the end of the company as a pure cannabis player, and possibly the end of the road in Israel for what until not so long ago was…

Kazyaka/iStock via Getty Images Cannabis analytics firm New Frontier Data sees brighter days for the US cannabis industry, projecting $71 billion in legal marijuana sales in 2030 if the current trend of state legalization continues even…